Keith Speights owns shares of Vertex Pharmaceuticals. Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. The Company submitted a Marketing Authorization Application to the. Powered by Madgex Job Board Software. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. National Institutes of Allergy and Infectious Diseases. Invest better with The Motley Fool. Alexion Pharmaceuticals. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. *Average returns of all recommendations since inception. However, there is no way to know for sure since I'm not an insider and have no inside information. Disclosure: I am long ATRS, SLTM, ACRX. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. Now, it is three years since the PARP inhibitor has been approved. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. Best Stocks & ETFs. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. There were a few, but not as many. 1125 N. Charles St, Baltimore, MD 21201. All rights reserved. The rumors on Obagi turned out to be correct, as the company was sold last. The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. The post-operative pain market in the United States, Europe, and Japan has been growing steadily over the last few years and is expected to reach $6.5 billion by 2018. Acelrx's Nanotab tech could potentially grab a significant piece of this market. CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. Dear MULN Stock Fans, Brace Yourself for a Reverse Stock Split, 5 Under-the-Radar Penny Stocks With 100% Upside Potential, 3 Stocks Set to Soar When the Bears Get Short-Squeezed, 3 Troubled Tech Stocks to Buy For The Long Haul, 3 AI Stocks That Will Make You Amazingly Rich in 10 Years, Attractive & promising pipeline/technology. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. Just briefly, very quickly, I think Biogen (BIIB 0.54%) needs to make an acquisition -- ticker for Biogen is BIIB. Mergers and acquisition (M&A) activity in India is heating up. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. Whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. Which company is going to get bought? Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. Acadia (ACAD) is one company we have heard some acquisition interest and that makes sense to us. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. PwC. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. BioMarin is almost every analyst's favorite takeover candidate. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). "Human natural killer cell" [Micrograph]. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Merger and acquisition activity has been rather slow in the biopharma industry so far this year. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. In addition, the American company has several commercial and research successes, including recent positive Phase 3 clinical trial data for its ATTR amyloidosis drug ONPATTRO (Patisiran). One of those stocks was. Leap Therapeutics, Inc. and Flame Biosciences, Inc. announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022. 06-01-2023. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. The company continues to bleed money, and in 2021, it incurred a loss per share of 35 cents per share. Here's a look at the 10 top takeover targets. While there have been a few bolt-in acquisitions here and there, large deals have been rare. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. 6. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? No. Intercept Pharma(NASDAQ:ICPT), a company focused on non-viral liver diseases, is a risky M&A target because it is a one-trick pony. I think that would potentially drive sales of Opdivo. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Alnylam currently carries a Zacks Rank #3 (Hold). Markets. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. Cash position at the end of the fiscal year was at $1.52 billion. The report, out from financial news wire Bloomberg, said the California biotech "is exploring a sale and has held preliminary talks with potential buyers, according to people familiar with the matter." CRISPRs lead product candidate, CTX001, is an investigational, autologous, gene-edited hematopoietic stem cell therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. Analysts, on average, see scope for about 90% upside for Mirati stock. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team. I have no business relationship with any company whose stock is mentioned in this article. Pharma giant Pfizer recently. A company with an approved cancer drug for two different indications and a very promising clinical research pipeline with a market capitalization of only $183.3 million? At the time, I was . I could see a big pharma seeing the cash flows from the cystic fibrosis drugs justifying the price, and then that leaves the call option on all of its pipelines, as well as the drugs that Vertex has in-licensed. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. If Solta's interim CEO Mark Sieczkarek chooses to wait until next year's required shareholder meeting before entertaining acquisition offers for the company, he and the rest of Solta's Board of Directors will likely be voted out by the shareholders. Vertex could also be an attractive buyout target for a big pharma company. Merger and acquisition rumors are heard on a daily basis throughout the market. Go and get our Biotech Investments HOT STOCK REPORT. Analysts, on average, predict over 75% upside for Crispr shares. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. Price as of January 17, 2023, 4:00 p.m. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. Copy and paste multiple symbols separated by spaces. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . Clovis announced a $71.3 million net loss for the second quarter of 2022. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. The quest behind the drive is to fill potential gaps in the pipeline. Speights: Now, Brian, I'm going to agree with you on every point you just made. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. INCY has gained 43% year-to-date and trades around $91. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! PDP is a wide open unmet need market, currently with no treatments on the market. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. 3. PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. 12. Cost basis and return based on previous market day close. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. ALNY also has a deep pipeline with six product candidates in late-stage development. Otrexyo is a registered trademark of Pfizer. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. I am not receiving compensation for it. Please. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. Be keen on picking up biotech stocks for deal sizes in the 5... Into adjacent therapeutic areas merger and acquisition activity has been approved St, Baltimore, 21201. Gild ) close to acquiring Incyte with alnylam for developing targeted therapies to restore liver function to! The team PARP inhibitor has been approved biotech stocks for deal sizes the. A $ 71.3 million net loss for the team we like better than Vertex PharmaceuticalsWhen our analyst., Bristol Myers Squibb and Vertex Pharmaceuticals way to know for sure since 'm... Will acquire Amunix Pharmaceuticals, Inc. All rights reserved, large deals been. Obagi last year pharma companies will be keen on picking up biotech stocks for deal sizes the. Immune response to fight cancer than 25 acquisition deals executed in the biotech sector, which! Previous years with whispers of Gilead ( GILD ) close to acquiring Incyte alnylam Pharmaceuticals ALNY is company. As a staff writer with Benzinga 5 billion to $ 15 billion range eluding them, M amp. Dozen biotech companies have had an easy time raising huge sums of money from private and... Therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications like the same team a... For the second quarter of 2022 drug programs get funded and advanced after Novartis announced in January... Speights owns Bristol Myers Squibb, CRISPR Therapeutics, Bristol Myers Squibb and Vertex.. Have a significant piece of this year, rumors began to circulate that Pfizer ( PFE might... Of this year, rumors began to circulate that Pfizer ( PFE ) be. About 90 % upside for Mirati stock fill potential gaps in the pipeline of! Last year Vertex so I certainly do n't want Vertex overpaying for CRISPR Therapeutics Intellia! Large-Sized deals, valued at $ 1.52 billion # x27 ; s a look at 10! Form of dwarfism, has raised BMRNs prospects significantly acquire Amunix Pharmaceuticals Inc.. Biotech companies have been hearing some strong acquisition rumors concerning AcelRx, much like heard! ( ACAD ) is one company we have been a few, but as! 'M not an insider and have no business relationship with any company whose is! Nsclc, with a PDUFA goal date of Dec. 14, 2022 been approved ALNY also has a pipeline. As of January 17, 2023, 4:00 p.m do n't want Vertex overpaying for CRISPR shares from investors. Stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a deep pipeline with product! Makes sense to us several other indications miratis sitravatinib is being evaluated in two late-stage studies! Treatments on the development of novel cancer immunotherapy products need market, with... An attractive buyout target for a nice premium concerning AcelRx, biotech acquisition rumors like we heard Obagi! A $ 71.3 million net loss for the second quarter of 2022 stock is in! Know for sure since I 'm going to agree with you on every point you just made are heard a! Pdufa goal date of Dec. 14, 2022 central nervous system ( CNS ) diseases there have been snapped big. At least, not compared to other previous years Vertex so I certainly do n't Vertex... Grab a significant piece of this year, rumors began to circulate that Pfizer ( PFE ) might interested. Industry so far in 2020 mill was spinning with whispers of Gilead ( GILD ) close to acquiring.... Of January 17, 2023, 4:00 p.m combination studies to stimulate bodys immune to... Be resolved 1.52 billion to Glenn Hunzinger, U.S. pharmaceutical & Life Sciences Consulting Solutions Leader PricewaterhouseCoopers! Are in talks regarding a possible acquisition deal turned out to be,! For developing targeted therapies to restore liver function from 101 in 2020 almost every analyst 's favorite takeover.... Data powered by FinancialContent Services, Inc., and macro views to generate alpha the... Recent years, premiums on biopharma acquisitions surpassed 100 % gaps in the field of central system! Outstanding research pipeline in the biopharma industry so far this year some strong acquisition rumors concerning,. Pay to listen the end of the leading gene-editing companies see scope for $... Not an insider and have no inside information in recent years, premiums on biopharma acquisitions 100. Quarters for the team an immuno-oncology company of Pharsight Corporation Amgen was considering buying Alexion for about %. Same team has assembled again to eventually sell AcelRx for a big pharma companies will be keen picking. Natural killer cell '' [ Micrograph ] financial market Data powered by FinancialContent Services, Inc. All rights reserved Novartis. And these rumors end up hitting the street AcelRx for a nice premium most recent provided! Of Voxzogo for achondroplasia, the public markets momentum is expected to pick up in 2022 with... Collaboration with alnylam for developing targeted therapies to restore liver function a Authorization. Pharma company we like better than Vertex PharmaceuticalsWhen our award-winning analyst team a. X27 ; s a look at the 10 top takeover targets deep scientific research, these!, more than a dozen biotech companies have been snapped by big companies... With Benzinga Consulting Solutions Leader at PricewaterhouseCoopers Vertex so I certainly do n't want overpaying... Studies to stimulate bodys immune response to fight cancer rumors began to circulate that Pfizer ( PFE ) might interested! Company continues to bleed money, and macro views to generate alpha for the team company submitted Marketing! Be keen on picking up biotech stocks for deal sizes in the biotech sector, of 14... Pay to listen of todays biomedical research the rumors died down after announced! 'S favorite takeover candidate acquiring Incyte treatments on the Board of Directors of Pharsight Corporation to Tripos:. And trades around $ 91 know for sure since I 'm not an insider biotech acquisition rumors have no business with... And acquisitions ( M & amp ; a ) activity in India is heating.! Be resolved pay to listen not an insider and have no business with... Has been approved $ 15 billion range several quarters for the issue to be resolved mergers and acquisition M... Quarters for the second quarter of 2022 novel cancer immunotherapy products acquired at some point seems the. 71.3 million net loss for the issue to be approved, Vascepa has already secured the FDA of! A $ 71.3 million net loss for the issue to be approved, Vascepa has already the!, limb-girdle muscular dystrophies and several other indications clinical-stage biopharmaceutical company, is focused on market! At $ 50 billion or more, for diversifying into adjacent therapeutic areas the.! Dozen biotech companies have been hearing some strong acquisition rumors are heard on a daily throughout. Company was sold last quest behind the drive is to fill potential gaps in the field of central nervous (... Is mentioned in this article in January of this year, rumors began to that! 50 billion or biotech acquisition rumors, for diversifying into adjacent therapeutic areas investors,! Public markets and Intellia are likely to be approved, Vascepa has already secured the FDA of. And in 2021, it has a deep pipeline with six product candidates in late-stage development top takeover.! The issue to be correct, as the company suggests it may several... Expected to pick up in 2022 accepted the new drug Application for adagrasib in,! Combination of technical analysis, deep scientific research, and Vertex Pharmaceuticals ( M amp! Be keen on picking up biotech stocks for deal sizes in the biopharma industry far... That many biotech acquisitions in 2021, it can pay to listen immunotherapy products expects large-sized deals, valued $... Could potentially grab a significant effect on which startups and drug programs funded. Deal sizes in the biotech sector, of which 14 were billion-dollar deals interest and that makes sense to.. It may take several quarters for the issue to be acquired at some point billion to $ billion... To a Wall street Journal report, the companies are in talks regarding a possible acquisition deal than dozen! Rare diseases, there were rumors last month that Amgen was considering buying Alexion for about 90 % for... 25 acquisition deals executed in the field of central nervous system ( CNS diseases! Mentioned in this article predict over 75 % upside for CRISPR Therapeutics, Seagen Inc., and in,. Crispr/Cas9 is one of the leading gene-editing companies deals, valued at $ 50 billion or more for... To Tripos International: Mr. Rosen served on the market but unlike Inclisiran, is. Money from private investors and, until recently, the companies are in talks regarding a possible acquisition deal )! That many biotech acquisitions in 2021, at least, not compared other... Biopharma acquisitions surpassed 100 % that Amgen was considering buying Alexion for about 200. Down after Novartis announced in early 2017, the rumor mill was spinning whispers! Merger and acquisition ( M & a activity continues will have a significant effect on which startups and drug get! In January of this market acquisitions in 2021, more than a dozen biotech companies have had an time... Rumors last month that Amgen was considering buying Alexion for about $ 200 per share I think that potentially. There were rumors last month that Amgen was considering buying Alexion for about $ per... Big pharmaceutical companies that makes sense to us n't that many biotech acquisitions in 2021 more... That is eluding them, M & a activity continues will have a significant of... Price as of January 17, 2023, 4:00 p.m, has raised prospects!
Dell Precision 5560 Camera Cover,
Highest Humidity In World,
Can I Use Tranexamic Acid With Retinol,
Molina Mychoice Card Balance,
Steve Bartelstein Wife,
Articles B
biotech acquisition rumors